Literature DB >> 20348143

The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines.

Ron Pisters1, Robert J van Oostenbrugge, Iris L H Knottnerus, Cees B de Vos, Anita Boreas, Jan Lodder, Martin H Prins, Harry J G M Crijns, Robert G Tieleman.   

Abstract

AIMS: Despite the known increased stroke risk associated with AF and the benefit of oral anticoagulation (OAC) in high-risk patients, still approximately 20% of all ischaemic strokes are atrial fibrillation (AF) related. We aimed to evaluate the frequency of inappropriate anticoagulation in all patients admitted with AF associated ischaemic stroke and calculate the theoretical number of preventable strokes in case of proper guideline adherence and assess secondary stroke prevention at discharge. METHODS AND
RESULTS: In this cross-sectional study, all patients with ischaemic strokes admitted to our hospital during May 2003-August 2006 in whom the diagnosis AF was either known or established during hospital stay were identified. We studied if their admission and discharge antithrombotic therapy was in accordance with the published guidelines. Subsequently, we calculated the number of preventable strokes in case AF patients would have received adequate antithrombotic treatment on admission. On admission, in 51% of the OAC eligible known AF patients the drug was withheld. Improved antithrombotic guideline adherence potentially would have prevented 20 out of the 89 (22%) ischaemic strokes. At discharge at least 10% of the patients were still insufficiently protected against recurrent stroke.
CONCLUSION: Many known AF patients admitted with ischaemic stroke lack adequate antithrombotic treatment on admission. Antithrombotic guideline adherence in these patients has the potential to prevent a substantial number strokes. Secondary stroke prevention at discharge is also suboptimal.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20348143     DOI: 10.1093/europace/euq080

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  15 in total

Review 1.  Underprescription of beneficial medicines in older people: causes, consequences and prevention.

Authors:  Antonio Cherubini; Andrea Corsonello; Fabrizia Lattanzio
Journal:  Drugs Aging       Date:  2012-06-01       Impact factor: 3.923

2.  Screening For Atrial Fibrillation In The Community Using A Novel ECG Recorder.

Authors:  Irma Battipaglia; Katrina Gilbert; Andrew J Hogarth; Muzahir H Tayebjee
Journal:  J Atr Fibrillation       Date:  2016-08-31

Review 3.  Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation.

Authors:  A John Camm; Fausto J Pinto; Graeme J Hankey; Felicita Andreotti; F D Richard Hobbs
Journal:  Europace       Date:  2015-07       Impact factor: 5.214

4.  Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination.

Authors:  Femke Kaasenbrood; Monika Hollander; Frans H Rutten; Leo J Gerhards; Arno W Hoes; Robert G Tieleman
Journal:  Europace       Date:  2016-02-06       Impact factor: 5.214

Review 5.  Empirical anticoagulation for patients in sinus rhythm at high risk of ischaemic stroke: A review of current literature.

Authors:  Irma Battipaglia; James O'Neill; Andrew J Hogarth; Muzahir H Tayebjee
Journal:  World J Cardiol       Date:  2017-05-26

6.  Detecting and Diagnosing Atrial Fibrillation (D2AF): study protocol for a cluster randomised controlled trial.

Authors:  Steven B Uittenbogaart; Nicole Verbiest-van Gurp; Petra M G Erkens; Wim A M Lucassen; J André Knottnerus; Bjorn Winkens; Henk C P M van Weert; Henri E J H Stoffers
Journal:  Trials       Date:  2015-10-23       Impact factor: 2.279

7.  Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.

Authors:  Jelena Stevanović; Marjolein Pompen; Hoa H Le; Mark H Rozenbaum; Robert G Tieleman; Maarten J Postma
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

8.  Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation.

Authors:  R G Tieleman; Y Plantinga; D Rinkes; G L Bartels; J L Posma; R Cator; C Hofman; R P Houben
Journal:  Europace       Date:  2014-05-13       Impact factor: 5.214

9.  Risk scores and geriatric profile: can they really help us in anticoagulation decision making among older patients suffering from atrial fibrillation?

Authors:  Frédéric Maes; Olivia Dalleur; Séverine Henrard; Dominique Wouters; Christophe Scavée; Anne Spinewine; Benoit Boland
Journal:  Clin Interv Aging       Date:  2014-07-15       Impact factor: 4.458

Review 10.  Optimal long-term antithrombotic management of atrial fibrillation: life cycle management.

Authors:  R Pisters; A Elvan; H J G M Crijns; M E W Hemels
Journal:  Neth Heart J       Date:  2018-06       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.